Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 82-86

  Tragiannidis, A ^a,b   Groll, A H ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cytokines; Hyperbaric oxygen; Iron chelation; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; PLACEBO; POSACONAZOLE; SIDEROPHORE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANTIFUNGAL ACTIVITY; CANCER PATIENT; CYTOKINE RELEASE; DIABETIC KETOACIDOSIS; FUNGICIDAL ACTIVITY; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPROMISED PATIENT; IRON CHELATION; MORTALITY; MUCORMYCOSIS; NONHUMAN; OVERALL SURVIVAL; OXYGEN TRANSPORT; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY BURST; REVIEW; SURVIVAL RATE; ZYGOMYCETES;

ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEBRIDEMENT; ECHINOCANDINS; HUMANS; HYPERBARIC OXYGENATION; IMMUNOLOGIC FACTORS; OXYGEN; TRIAZOLES; ZYGOMYCOSIS;

EID: 70349994625     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02986.x     Document Type: Review

References (52)

1. Sugar AM. Mucormycosis. Clin Infect Dis 1992, 14(suppl 1):126-129.
2. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002, 16:895-914.
3. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004, 17:517-525.
4. Kauffman CA. Zygomycosis: re-emergence of an old pathogen. Clin Infect Dis 2004, 39:588-590.
5. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary care cancer centre. Clin Infect Dis 2000, 30:851-856.
6. Prokopowicz GP, Bradley SF, Kauffman CA. Indolent zygomycosis associated with deferoxamine chelation therapy. Mycoses 1994, 37:427-431.
7. Hopkins RJ, Rothman M, Fiore A, Goldblum SE. Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994, 19:1133-1137.
8. Van den Saffele JK, Boelaert JR. Zygomycosis in HIV-positive patients: a review of the literature. Mycoses 1996, 39:77-84.
9. Roden MM, Zaoutis T, Buchanan W. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
10. Kontoyiannis D, Lewis R. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006, 20:581-607.
11. Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008?. Clin Microbiol Infect 2008, 14(suppl 4):71-83.
12. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008, 61(suppl 1):35-40.
13. Okhuysen PC, Rex JH, Kapusta M, Fife C. Successful treatment of extensive post-traumatic soft-tissue and renal infections due to Apophysomyces elegans. Clin Infect Dis 1994, 19:329-331.
14. Garcia-Covarrubias L, Bartlett R, Barratt DM, Wassermann RJ. Rhino-orbitocerebral mucormycosis attributable to Apophysomyces elegans in an immunocompetent individual: case report and review of the literature. J Trauma 2001, 50:353-357.
15. Mathieu D, Wattel F, Mathieu D. Physiologic effects of hyperbaric oxygen on microorganisms and host defences against infection. Handbook on Hyperbaric Medicine 2006, 103-119. In, ed, Dordrecht, Springer
16. Park M, Kindwall EP, Whelan HT. Effects of hyperbaric oxygen in infectious diseases: basic mechanisms. Hyperbaric Medicine Practice 1999, 205-243. In, eds, 2nd edn, Flagstaff, AZ, Best Publishing Company
17. Gudewicz TM, Mader JT, Davis CP. Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans. Aviat Space Environ Med 1987, 58:673-678.
18. Guidelines: Indications for Hyperbaric Oxygen 2000, Kensington, MD, UHMS
19. Leach RM, Rees P, Wilmshurst P. ABC of oxygen. Hyperbaric oxygen therapy. BMJ 1998, 317:1140-1143.
20. Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis 2006, 43:188-192.
21. Bitterman H. Oxygen: an anti-inflammatory drug. Isr Med Assoc J 2007, 9:874-876.
22. Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am 2008, 26:571-595.
23. Galliazzo F, Schiesser A, Rotilio G. Glutathione peroxidise in yeast. Presence of the enzyme and induction by oxidative conditions. Biochem Biophys Res Commun 1987, 18:974-979.
24. Siddiqui A, Davidson JD, Mustoe TA. Ischaemic tissue oxygen capacitance after hyperbaric oxygen therapy: a new physiologic concept. Plast Reconstr Surg 1997, 99:148-155.
25. Gimbel M, Hunt T, Kindwall EP, Whelan TH. Wound healing and hyperbaric oxygenation. Hyperbaric Medicine Practice 1999, 169-204. In, eds, 2nd edn, Flagstaff, AZ, Best Publishing Company
26. Sokol-Anderson M, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986, 154:76-83.
27. Barratt DM, Van Meter K, Asmar P. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trials in a murine model. Antimicrob Agents Chemother 2001, 45:3601-3602.
28. Fergusons BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1998, 10:551-559.
29. Segal E, Menhusen MJ, Shawn S. Hyperbaric oxygen in the treatment of invasive fungal infections: a single-centre experience. Isr Med Assoc J 2007, 9:387-388.
30. John B, Chamilos G, Kontoyiannis D. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515-517.
31. Gill-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn R, Walsh T. Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes. J Infect Dis 2005, 191:1180-1187.
32. Roilides E, Lyman CA, Panagopoulou P, Chanock S. Immunomodulation of invasive fungal infections. Infect Dis Clin North Am 2003, 17:193-219.
33. Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 1998, 57:7-15.
34. Kapp A, Zeck-Kapp G. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immunomodulating cytokines. J Invest Dermatol 1990, 95(suppl 6):94-99.
35. Al-Shami A, Mahanna W, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signalling pathways in human neutrophils. Selective activation of Jak2, Stat3, and Stat5b. J Biol Chem 1998, 273:1058-1063.
36. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998, 42:2299-2303.
37. Gaviria JM, van Burik JA, Dale DC, Root RK, Liles WC. Comparison of interferon-γ, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999, 179:1038-1041.
38. Chaves MM, Silvestrini AA, Silva-Teixeira DN, Nogueira-Machado JA. Effect in vitro of gamma interferon and interleukin-10 on generation of oxidizing species by human granulocytes. Inflamm Res 1996, 45:313-315.
39. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997, 175:1012-1015.
40. Sahin B, Paydas S, Cosar E, Bicakci K, Hazar B. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis 1996, 15:866-869.
41. Garcia-Diaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis 2001, 32:145-150.
42. Bullen J, Rogers H, Spalding P, Ward C. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006, 55:251-258.
43. Schaible U, Kaufmann S. Iron and microbial infection. Nat Rev Microbiol 2004, 2:946-953.
44. De Locht M, Boelaert J, Schneider Y. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994, 47:1843-1850.
45. Boelaert J, Van Cutsem J, de Locht M, Schneider Y, Crichton R. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994, 45:667-671.
46. Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 1990, 110:87-91.
47. Boelaert J, de Locht M, van Cutsen J. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993, 91:1979-1986.
48. Ibrahim A, Edwards J, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070-1073.
49. Van Cutsem J, Boelaert J. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989, 36:1061-1068.
50. Ibrahim A, Gebermariam T, Fu Y. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2650-2657.
51. Reed C, Ibrahim A, Edwards J, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968-3969.
52. Soummer A, Mathonnet A, Scatton O. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother 2008, 52:1585-1586.